Please assess the completion status of the following clinical trial:

Trial Title: Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented breast cancer~* Clinical evidence of mets to the liver~* Performance status of 0-2~* Life expectancy of greater equal to 3 months~* Not pregnant~* 4 weeks or more since last radiation therapy~* Recovered from all side effects of prior chemotherapy~* Not needing concurrent chemotherapy~* recovered laboratory values~* Bilirubin \< 2.0~Exclusion Criteria:~* Candidate for surgical resection or ablation of liver lesion/s~* Prior radiation therapy to the liver~* Co-Morbid disease~* pulmonary insufficiency~* Portal vein thrombosis~* Contraindications to angiography~* \> 20 % lung shunting on MAA~* Diffuse extra-hepatic disease~* Concurrent chemotherapy OR capecitabine with 8 weeks~* Failed MAA~* Uncontrolled active infection~* Severe liver dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): All patients will be treated with SIR-Sphere therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).